

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|--------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Superior Palmarbal Nasal Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 1.1 (1.06) | 1.6 (0.90) | 1.5 (1.11) | 1.4 (1.03) |
| | | Median | 1.0 | 1.5 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 2.0 | 1.0, 2.0 | 1.0, 3.0 | 1.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 0.7 (0.90) | 1.3 (0.93) | 1.2 (1.19) | 1.1 (1.03) |
| | | Median | 0.5 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 1.0, 2.0 | 0.0, 3.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -0.4 (0.92) | -0.3 (0.77) | -0.3 (0.71) | -0.3 (0.79) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 1 | -2, 1 | -3, 1 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 1 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|--------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Superior Palmarbal Nasal Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 0.7 (0.90) | 1.4 (1.05) | 1.1 (1.07) | 1.1 (1.04) |
| | | Median | 0.5 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 1.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -0.4 (0.88) | -0.2 (0.80) | -0.4 (0.81) | -0.3 (0.83) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | 0.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 2 | -2, 1 | -3, 2 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 0.5 (1.02) | 1.1 (1.01) | 1.2 (1.20) | 1.0 (1.11) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.5 | 0.0, 1.5 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 2 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Superior Parolimbic Nasal Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -0.5 (1.10) | -0.5 (0.79) | -0.3 (0.82) | -0.4 (0.90) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 2 | -2, 1 | -2, 1 | -3, 2 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 0.5 (0.78) | 1.1 (1.11) | 1.1 (1.21) | 0.9 (1.08) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -0.5 (0.83) | -0.4 (0.84) | -0.5 (0.89) | -0.5 (0.84) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -2, 1 | -2, 1 | -3, 1 | -3, 1 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 3 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Inferior Paralimbal Nasal Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 1.4 (0.98) | 1.5 (0.94) | 1.8 (1.17) | 1.6 (1.03) |
| | | Median | 1.0 | 1.0 | 2.0 | 2.0 |
| | | Q1, Q3 | 1.0, 2.0 | 1.0, 2.0 | 1.0, 3.0 | 1.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 0.9 (0.88) | 1.2 (0.88) | 1.4 (1.17) | 1.2 (1.00) |
| | | Median | 1.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 1.0, 2.0 | 0.0, 3.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -0.5 (0.92) | -0.4 (0.68) | -0.3 (0.96) | -0.4 (0.86) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 1 | -3, 2 | -3, 2 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 4 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Inferior Paralimbal Nasal Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 0.8 (0.84) | 1.4 (0.95) | 1.3 (1.08) | 1.1 (0.99) |
| | | Median | 1.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 1.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -0.7 (0.82) | -0.1 (0.86) | -0.5 (0.86) | -0.4 (0.87) |
| | | Median | -0.5 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 0 | -1, 3 | -2, 1 | -3, 3 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 0.9 (0.97) | 1.2 (0.83) | 1.4 (1.23) | 1.2 (1.04) |
| | | Median | 1.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 1.0, 2.0 | 0.0, 3.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 5 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Inferior Paralimbal Nasal Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -0.5 (0.93) | -0.4 (0.78) | -0.3 (0.81) | -0.4 (0.83) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -2, 2 | -2, 2 | -2, 2 | -2, 2 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 0.7 (0.86) | 1.4 (0.95) | 1.4 (1.21) | 1.2 (1.06) |
| | | Median | 0.5 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 1.0, 2.0 | 0.0, 3.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -0.6 (0.88) | -0.2 (0.55) | -0.4 (0.97) | -0.4 (0.82) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -0.5, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -2, 1 | -1, 1 | -3, 2 | -3, 2 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 6 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Peripheral Nasal Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 1.1 (1.16) | 1.2 (1.09) | 1.7 (1.21) | 1.3 (1.17) |
| | | Median | 1.0 | 1.0 | 2.0 | 1.0 |
| | | Q1, Q3 | 0.0, 2.0 | 0.0, 2.0 | 1.0, 3.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 0.5 (0.79) | 1.0 (0.90) | 1.3 (1.20) | 0.9 (1.02) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 1.5 | 0.0, 3.0 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -0.6 (0.92) | -0.2 (0.88) | -0.4 (0.81) | -0.4 (0.87) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 0 | -2, 2 | -2, 1 | -3, 2 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 7 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Peripheral Nasal Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 0.5 (0.79) | 1.2 (1.08) | 1.3 (1.11) | 1.0 (1.05) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -0.6 (0.87) | 0.0 (0.87) | -0.4 (0.72) | -0.3 (0.86) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | 0.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -2, 1 | -1, 3 | -2, 1 | -2, 3 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 0.5 (0.78) | 0.9 (0.90) | 0.9 (1.21) | 0.8 (1.00) |
| | | Median | 0.0 | 1.0 | 0.0 | 0.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 8 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Peripheral Nasal Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -0.7 (1.04) | -0.3 (0.71) | -0.8 (0.97) | -0.6 (0.92) |
| | | Median | 0.0 | 0.0 | -0.5 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 1 | -3, 0 | -3, 1 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 0.4 (0.58) | 0.9 (1.03) | 1.0 (1.26) | 0.8 (1.03) |
| | | Median | 0.0 | 1.0 | 0.0 | 0.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 1.0 |
| | | Min, Max | 0, 2 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -0.6 (1.01) | -0.3 (0.67) | -0.6 (1.04) | -0.5 (0.92) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -1, 1 | -3, 1 | -3, 1 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 9 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Nasal Section Total Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 3.7 (2.89) | 4.2 (2.70) | 5.0 (3.27) | 4.3 (2.98) |
| | | Median | 3.0 | 4.0 | 5.0 | 4.0 |
| | | Q1, Q3 | 1.0, 6.0 | 2.0, 6.0 | 2.0, 8.0 | 2.0, 7.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 2.1 (2.32) | 3.5 (2.53) | 3.9 (3.32) | 3.2 (2.84) |
| | | Median | 1.5 | 3.0 | 3.0 | 2.0 |
| | | Q1, Q3 | 1.0, 2.5 | 2.0, 5.5 | 2.0, 8.0 | 1.0, 5.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -1.5 (2.33) | -0.9 (1.99) | -1.1 (1.98) | -1.1 (2.09) |
| | | Median | 0.0 | -1.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -2.5, 0.0 | -2.0, 0.0 | -3.0, 0.0 | -2.0, 0.0 |
| | | Min, Max | -7, 1 | -6, 4 | -6, 2 | -7, 4 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 10 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Nasal Section Total Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 2.0 (2.23) | 4.0 (2.84) | 3.7 (3.07) | 3.2 (2.85) |
| | | Median | 1.0 | 4.0 | 3.0 | 2.0 |
| | | Q1, Q3 | 1.0, 2.0 | 2.0, 5.0 | 1.0, 6.0 | 1.0, 5.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -1.8 (2.17) | -0.2 (2.13) | -1.3 (1.99) | -1.1 (2.17) |
| | | Median | -1.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -2.5, 0.0 | -1.0, 0.0 | -3.0, 0.0 | -2.0, 0.0 |
| | | Min, Max | -7, 1 | -4, 8 | -6, 2 | -7, 8 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 1.9 (2.54) | 3.3 (2.49) | 3.5 (3.49) | 3.0 (2.94) |
| | | Median | 1.0 | 3.0 | 2.0 | 2.0 |
| | | Q1, Q3 | 0.0, 2.0 | 2.0, 5.0 | 1.0, 7.5 | 1.0, 5.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 11 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Nasal Section Total Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -1.8 (2.71) | -1.1 (1.87) | -1.4 (2.21) | -1.4 (2.25) |
| | | Median | -1.0 | -1.0 | -1.0 | -1.0 |
| | | Q1, Q3 | -3.5, 0.0 | -2.0, 0.0 | -3.0, 0.0 | -3.0, 0.0 |
| | | Min, Max | -7, 4 | -5, 4 | -7, 2 | -7, 4 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 1.7 (1.93) | 3.4 (2.77) | 3.5 (3.46) | 2.9 (2.90) |
| | | Median | 1.0 | 2.5 | 2.0 | 2.0 |
| | | Q1, Q3 | 0.0, 2.0 | 1.5, 5.0 | 0.0, 7.0 | 1.0, 5.0 |
| | | Min, Max | 0, 8 | 0, 9 | 0, 9 | 0, 9 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -1.7 (2.35) | -0.9 (1.59) | -1.5 (2.49) | -1.4 (2.16) |
| | | Median | -1.0 | -0.5 | 0.0 | -1.0 |
| | | Q1, Q3 | -3.0, 0.0 | -2.0, 0.0 | -2.0, 0.0 | -2.0, 0.0 |
| | | Min, Max | -7, 1 | -4, 3 | -8, 2 | -8, 3 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 12 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|--------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Superior Palmar Temporal Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 1.1 (1.09) | 1.4 (0.81) | 1.6 (1.14) | 1.4 (1.03) |
| | | Median | 1.0 | 1.0 | 2.0 | 1.0 |
| | | Q1, Q3 | 0.0, 2.0 | 1.0, 2.0 | 1.0, 3.0 | 1.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 0.6 (0.88) | 1.0 (0.92) | 1.2 (1.17) | 1.0 (1.02) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -0.5 (0.96) | -0.4 (0.57) | -0.3 (0.80) | -0.4 (0.79) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -1, 1 | -2, 1 | -3, 1 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 13 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|--------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Superior Palmar Temporal Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 0.6 (0.91) | 1.1 (0.95) | 1.1 (1.21) | 1.0 (1.05) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -0.5 (0.96) | -0.3 (0.75) | -0.5 (0.97) | -0.4 (0.90) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 1 | -3, 1 | -3, 1 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 0.5 (0.98) | 1.0 (1.00) | 1.0 (1.19) | 0.9 (1.08) |
| | | Median | 0.0 | 1.0 | 1.0 | 0.5 |
| | | Q1, Q3 | 0.0, 0.5 | 0.0, 1.0 | 0.0, 1.5 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 14 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|----------------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Superior Palimbil Temporal Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -0.6 (1.06) | -0.4 (0.69) | -0.6 (0.88) | -0.5 (0.87) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.5, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 1 | -3, 1 | -3, 1 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 0.5 (0.83) | 1.0 (1.07) | 1.2 (1.18) | 0.9 (1.07) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -0.5 (1.06) | -0.4 (0.79) | -0.4 (0.85) | -0.4 (0.89) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 1 | -2, 1 | -3, 1 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 15 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|-------------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Inferior Palmaribbal Temporal Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 1.3 (1.14) | 1.3 (1.03) | 1.6 (1.10) | 1.4 (1.09) |
| | | Median | 1.0 | 1.0 | 2.0 | 1.0 |
| | | Q1, Q3 | 0.0, 2.0 | 1.0, 2.0 | 1.0, 3.0 | 1.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 0.8 (0.75) | 1.0 (0.96) | 1.3 (1.09) | 1.0 (0.97) |
| | | Median | 1.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 1.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -0.5 (0.84) | -0.4 (0.56) | -0.3 (0.69) | -0.4 (0.71) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 0 | -2, 0 | -2, 1 | -3, 1 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 16 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Inferior Palisimbil Temporal Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 0.7 (0.76) | 1.0 (0.96) | 1.3 (1.06) | 1.0 (0.96) |
| | | Median | 1.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -0.6 (0.91) | -0.4 (0.94) | -0.3 (0.75) | -0.4 (0.87) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 0 | -3, 2 | -2, 1 | -3, 2 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 0.8 (0.94) | 1.1 (0.86) | 1.1 (1.11) | 1.0 (0.98) |
| | | Median | 0.5 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 17 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Inferior Palisimbil Temporal Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -0.6 (1.06) | -0.4 (0.83) | -0.5 (0.84) | -0.5 (0.90) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 2 | -2, 2 | -2, 1 | -3, 2 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 0.7 (0.69) | 1.2 (0.98) | 1.3 (1.10) | 1.1 (0.97) |
| | | Median | 1.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 2 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -0.5 (0.83) | -0.3 (0.59) | -0.4 (0.80) | -0.4 (0.74) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -2, 1 | -1, 1 | -2, 1 | -2, 1 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 18 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Peripheral Temporal Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 0.9 (1.11) | 1.1 (1.05) | 1.3 (1.18) | 1.1 (1.11) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 | 0.0, 2.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 0.5 (0.96) | 0.8 (0.88) | 1.1 (1.14) | 0.8 (1.02) |
| | | Median | 0.0 | 1.0 | 1.0 | 0.0 |
| | | Q1, Q3 | 0.0, 0.5 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -0.4 (0.99) | -0.4 (0.49) | -0.2 (0.83) | -0.3 (0.80) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | 0.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 2 | -1, 0 | -2, 1 | -3, 2 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 19 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Peripheral Temporal Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 0.5 (0.79) | 0.8 (0.85) | 1.1 (1.11) | 0.8 (0.95) |
| | | Median | 0.0 | 1.0 | 1.0 | 1.0 |
| | | Q1, Q3 | 0.0, 1.0 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -0.4 (0.79) | -0.3 (0.70) | -0.2 (1.02) | -0.3 (0.85) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | 0.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -2, 1 | -2, 1 | -3, 2 | -3, 2 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 0.4 (0.77) | 0.7 (0.81) | 1.0 (1.23) | 0.7 (0.99) |
| | | Median | 0.0 | 1.0 | 0.5 | 0.0 |
| | | Q1, Q3 | 0.0, 0.5 | 0.0, 1.0 | 0.0, 2.0 | 0.0, 1.0 |
| | | Min, Max | 0, 3 | 0, 3 | 0, 3 | 0, 3 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 20 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Peripheral Temporal Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -0.5 (0.88) | -0.4 (0.79) | -0.3 (1.15) | -0.4 (0.95) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -0.5, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 1 | -3, 2 | -3, 2 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 0.3 (0.53) | 0.6 (0.91) | 1.1 (1.28) | 0.7 (1.02) |
| | | Median | 0.0 | 0.0 | 1.0 | 0.0 |
| | | Q1, Q3 | 0.0, 0.0 | 0.0, 1.0 | 0.0, 3.0 | 0.0, 1.0 |
| | | Min, Max | 0, 2 | 0, 3 | 0, 3 | 0, 3 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -0.5 (0.93) | -0.5 (0.64) | -0.3 (1.23) | -0.4 (0.96) |
| | | Median | 0.0 | 0.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 | -1.0, 0.0 |
| | | Min, Max | -3, 1 | -2, 0 | -3, 2 | -3, 2 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 21 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Temporal Section Total Score | Baseline | n (missing) | 29 (0) | 30 (0) | 30 (0) | 89 (0) |
| | | Mean (SD) | 3.3 (3.15) | 3.8 (2.62) | 4.5 (3.22) | 3.9 (3.01) |
| | | Median | 2.0 | 4.0 | 4.0 | 4.0 |
| | | Q1, Q3 | 0.0, 7.0 | 1.0, 6.0 | 2.0, 8.0 | 1.0, 6.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |
| | Week 2 | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | 1.9 (2.34) | 2.9 (2.46) | 3.7 (3.16) | 2.8 (2.77) |
| | | Median | 1.0 | 2.5 | 3.0 | 2.0 |
| | | Q1, Q3 | 0.0, 2.0 | 1.0, 4.0 | 1.0, 5.0 | 1.0, 4.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |
| | Week 2 change from Baseline | n (missing) | 28 (1) | 28 (2) | 30 (0) | 86 (3) |
| | | Mean (SD) | -1.4 (2.49) | -1.1 (1.13) | -0.8 (1.98) | -1.1 (1.94) |
| | | Median | 0.0 | -1.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -2.0, 0.0 | -2.0, 0.0 | -1.0, 0.0 | -2.0, 0.0 |
| | | Min, Max | -8, 2 | -3, 0 | -6, 2 | -8, 2 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 22 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------------|-----------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Temporal Section Total Score | Week 4 | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | 1.9 (2.21) | 3.0 (2.54) | 3.5 (3.17) | 2.8 (2.74) |
| | | Median | 1.0 | 2.0 | 2.5 | 2.0 |
| | | Q1, Q3 | 0.5, 2.5 | 1.0, 5.0 | 1.0, 6.0 | 1.0, 4.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |
| | Week 4 change from Baseline | n (missing) | 28 (1) | 29 (1) | 30 (0) | 87 (2) |
| | | Mean (SD) | -1.6 (2.28) | -0.9 (1.98) | -0.9 (2.36) | -1.1 (2.21) |
| | | Median | -1.0 | -1.0 | 0.0 | -1.0 |
| | | Q1, Q3 | -2.5, 0.0 | -2.0, 0.0 | -2.0, 0.0 | -2.0, 0.0 |
| | | Min, Max | -7, 1 | -6, 4 | -7, 3 | -7, 4 |
| | Week 8 | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | 1.6 (2.48) | 2.8 (2.47) | 3.2 (3.36) | 2.6 (2.85) |
| | | Median | 1.0 | 2.5 | 2.0 | 2.0 |
| | | Q1, Q3 | 0.0, 2.0 | 1.0, 4.5 | 0.0, 6.0 | 0.0, 4.0 |
| | | Min, Max | 0, 9 | 0, 9 | 0, 9 | 0, 9 |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 23 of 24

Table 14.2-2.16: Summary of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Section | Visit | | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|------------------------------|------------------------------|-------------|------------------------------------|----------------------------------|----------------------------|----------------------------|
| Temporal Section Total Score | Week 8 change from Baseline | n (missing) | 24 (5) | 28 (2) | 28 (2) | 80 (9) |
| | | Mean (SD) | -1.8 (2.80) | -1.2 (1.75) | -1.4 (2.51) | -1.4 (2.35) |
| | | Median | -0.5 | -1.0 | -0.5 | -1.0 |
| | | Q1, Q3 | -3.5, 0.0 | -2.0, 0.0 | -2.5, 0.0 | -2.5, 0.0 |
| | | Min, Max | -8, 4 | -5, 4 | -8, 3 | -8, 4 |
| | | | | | | |
| | Week 12 | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | 1.5 (1.84) | 2.9 (2.73) | 3.6 (3.35) | 2.7 (2.84) |
| | | Median | 1.0 | 2.0 | 2.0 | 1.0 |
| | | Q1, Q3 | 0.0, 2.0 | 1.0, 4.5 | 1.0, 7.0 | 0.0, 4.0 |
| | | Min, Max | 0, 7 | 0, 9 | 0, 9 | 0, 9 |
| | | | | | | |
| | Week 12 change from Baseline | n (missing) | 24 (5) | 28 (2) | 27 (3) | 79 (10) |
| | | Mean (SD) | -1.5 (2.55) | -1.1 (1.41) | -1.1 (2.62) | -1.2 (2.22) |
| | | Median | 0.0 | -1.0 | 0.0 | 0.0 |
| | | Q1, Q3 | -2.5, 0.0 | -2.0, 0.0 | -3.0, 0.0 | -2.0, 0.0 |
| | | Min, Max | -8, 2 | -4, 1 | -7, 2 | -8, 2 |
| | | | | | | |

N: total number of patients per group, n: number of non-missing observations, SD: standard deviation, Q1, Q3: First and Third Quartile.

Program: T_conjnei.sas

Production date (time): 04APR2023 (11:44)

Page 24 of 24

Table 14.2-2.17: Analysis of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Parameter | Visit | | Adjusted Mean | | P-value |
|---------------|--------|--|---------------|----------------------|---------|
| | | | n | LS Mean (95% CI) | |
| Nasal Section | Week 2 | 1% Pro-ocular | 28 | -0.84 (-1.66, -0.03) | - |
| | | 0.5% Pro-ocular | 28 | -1.65 (-2.48, -0.83) | - |
| | | Placebo | 30 | -0.81 (-1.66, 0.03) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | -0.03 (-1.04, 0.98) | 0.957 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -0.84 (-1.86, 0.19) | 0.108 |
| | | | | | |
| | Week 4 | 1% Pro-ocular | 29 | -0.24 (-1.03, 0.56) | - |
| | | 0.5% Pro-ocular | 28 | -1.91 (-2.71, -1.11) | - |
| | | Placebo | 30 | -1.04 (-1.87, -0.20) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | 0.80 (-0.19, 1.79) | 0.113 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -0.87 (-1.89, 0.14) | 0.090 |
| | | | | | |
| | Week 8 | 1% Pro-ocular | 28 | -1.16 (-2.06, -0.26) | - |
| | | 0.5% Pro-ocular | 24 | -2.02 (-2.98, -1.06) | - |
| | | Placebo | 28 | -1.30 (-2.26, -0.33) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | 0.14 (-0.99, 1.26) | 0.809 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -0.73 (-1.92, 0.47) | 0.231 |
| | | | | | |

N: total number of patients per group. n: number of non-missing observations. CI: Confidence Interval. The change from baseline is analysed by means of an ANCOVA model by Visit with treatment as fixed effect and baseline measure and stratification factor (male, female: menopausal, female: non-menopausal) as covariates.

Program: T_aconnei.sas

Production date (time): 12MAY2023 (11:25)

Page 1 of 3

Table 14.2-2.17: Analysis of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Parameter | Visit | | Adjusted Mean | | P-value |
|------------------|---------|--|---------------|----------------------|---------|
| | | | n | LS Mean (95% CI) | |
| Nasal Section | Week 12 | 1% Pro-ocular | 28 | -0.74 (-1.61, 0.13) | - |
| | | 0.5% Pro-ocular | 24 | -1.83 (-2.77, -0.89) | - |
| | | Placebo | 27 | -1.04 (-1.98, -0.09) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | 0.30 (-0.77, 1.36) | 0.582 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -0.80 (-1.93, 0.34) | 0.167 |
| | | | | | |
| Temporal Section | Week 2 | 1% Pro-ocular | 28 | -1.02 (-1.76, -0.29) | - |
| | | 0.5% Pro-ocular | 28 | -1.55 (-2.30, -0.80) | - |
| | | Placebo | 30 | -0.49 (-1.24, 0.27) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | -0.54 (-1.45, 0.37) | 0.245 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -1.06 (-1.98, -0.14) | 0.024 |
| | | | | | |
| | Week 4 | 1% Pro-ocular | 29 | -0.69 (-1.50, 0.12) | - |
| | | 0.5% Pro-ocular | 28 | -1.54 (-2.35, -0.72) | - |
| | | Placebo | 30 | -0.43 (-1.27, 0.41) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | -0.26 (-1.26, 0.75) | 0.612 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -1.10 (-2.13, -0.08) | 0.035 |

N: total number of patients per group. n: number of non-missing observations. CI: Confidence Interval. The change from baseline is analysed by means of an ANCOVA model by Visit with treatment as fixed effect and baseline measure and stratification factor (male, female: menopausal, female: non-menopausal) as covariates.

Program: T_aconnei.sas

Production date (time): 12MAY2023 (11:25)

Page 2 of 3

Table 14.2-2.17: Analysis of Conjunctival Fluorescein Staining Total Score by NEI Scale (Full Analysis Set)

| Parameter | Visit | | Adjusted Mean | | P-value |
|------------------|---------|--|---------------|----------------------|---------|
| | | | n | LS Mean (95% CI) | |
| Temporal Section | Week 8 | 1% Pro-ocular | 28 | -1.07 (-1.99, -0.16) | - |
| | | 0.5% Pro-ocular | 24 | -1.87 (-2.85, -0.89) | - |
| | | Placebo | 28 | -0.98 (-1.96, -0.01) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | -0.09 (-1.24, 1.05) | 0.874 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -0.88 (-2.10, 0.33) | 0.151 |
| | | | | | |
| | Week 12 | 1% Pro-ocular | 28 | -0.96 (-1.85, -0.08) | - |
| | | 0.5% Pro-ocular | 24 | -1.70 (-2.67, -0.74) | - |
| | | Placebo | 27 | -0.61 (-1.56, 0.35) | - |
| | | LS Mean Difference, 1% Pro-ocular – Placebo (95% CI) | | -0.35 (-1.44, 0.74) | 0.520 |
| | | LS Mean Difference, 0.5% Pro-ocular – Placebo (95% CI) | | -1.10 (-2.26, 0.07) | 0.065 |
| | | | | | |

N: total number of patients per group. n: number of non-missing observations. CI: Confidence Interval. The change from baseline is analysed by means of an ANCOVA model by Visit with treatment as fixed effect and baseline measure and stratification factor (male, female: menopausal, female: non-menopausal) as covariates.

Program: T_aconnei.sas

Production date (time): 12MAY2023 (11:25)

Page 3 of 3